elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Rituximab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Rituximab
RIS
0.001
(Research Intensity Score)
Papers
86
Top papers
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
2022 · 781 citations
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
2022 · 239 citations
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
2019 · 743 citations
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2021 · 198 citations
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 · 2333 citations
IgG4-Mediated Neurologic Autoimmunities
2021 · 99 citations
Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report
2025 · 8 citations
Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
2021 · 70 citations
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma
2025 · 8 citations
Newest papers
Highlights from the 2025 ASH meeting: what’s new in lymphoma?
2026
Calcineurin inhibitor versus mycophenolate mofetil along with rituximab in non-genetic calcineurin inhibitor resistant steroid resistant nephrotic syndrome: retrospective observation from western India
2026
Multi-target Therapy with Rituximab plus Mycophenolate Mofetil versus Rituximab Monotherapy in Systemic Sclerosis–Associated Interstitial Lung Disease
2026
Anti-Contactin-1 Nodopathy Presenting With Dysphagia and Nephrotic Syndrome
2026
Preliminary evaluation of Chidamide in combination with novel [177Lu]Lu-DOTAGA-rituximab in rituximab-resistant Raji cells
2026
Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report
2025 · 8 citations
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma
2025 · 8 citations
Switching from anti-CD20 therapies to cladribine and vice versa – Analysis of a German relapsing multiple sclerosis cohort
2025 · 5 citations
Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety
2025 · 6 citations
Browse all papers →
Rituximab's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Rituximab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link